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ABSTRACT
The effect on diagnostic yield of testing sequential
stools was assessed during two hospital
epidemics of Clostridium difficile. Using a rapid
immunoassay, C. difficile-associated disease was
diagnosed in 237 diarrhoeal patients, of whom
204 (86%) were diagnosed from the first faeces
sample and 12 (5%) were diagnosed from follow-
up samples obtained within 1 week. The remain-
ing 21 (9%) patients yielded a positive test from
stools obtained >1 week after the initial negative
sample. It was concluded that repeated testing of
stools for C. difficile toxin is of value in controlling
outbreaks of C. difficile infection.
Keywords Clostridium difficile, diagnostic yield, diarr-
hoea, immunoassay, repeated tests, toxin detection
Original Submission: 19 November 2007; Revised
Submission: 28 January 2008; Accepted: 31 January
2008
Clin Microbiol Infect 2008; 14: 622–624
10.1111/j.1469-0691.2008.01999.x
Clostridium difficile-associated disease (CDAD) is
one of the most common hospital-acquired
infections [1]. Early recognition of CDAD patients
is of prime importance to prevent spread and
to enable rapid implementation of adequate
isolation and hygiene procedures and the initia-
tion of CDAD-specific therapy. For rapid diagno-
sis, a fast, one-step immunoassay (ICTAB;
Meridian Bioscience Europe, Boxtel, The Nether-
lands) is available for the detection of C. difficile
toxins A and B in faeces samples. Using the cell
cytotoxicity test as a reference standard, the
relative sensitivity and specificity, and positive
and negative predictive values of the ICTAB
assay were 91%, 97%, 70% and 99%, respectively
[2]; similarly, Diederen et al. [3] reported a rela-
tive sensitivity of 88.6% compared with the
cytotoxicity test.
Current guidelines for the diagnosis of CDAD
recommend analysis of additional samples for
C. difficile toxin when the first sample is negative
and clinical suspicion is high [4,5]. This recom-
mendation has been disputed in two published
studies [6,7]; however, both of these studies were
performed in an endemic situation. The purpose
of the present study was to assess the effect of
sequential analysis of stools on diagnostic yield
when using the ICTAB immunoassay as an
alternative to the cytotoxicity test in CDAD
outbreaks caused by C. difficile strains belonging
to PCR ribotypes 027 and 017.
A CDAD epidemic caused by C. difficile PCR
ribotype 027 ⁄ toxinotype III occurred in hospi-
tal A between April and September 2005, with the
incidence of CDAD increasing rapidly from 3.8 to
58.4 ⁄ 10 000 admissions. At a distance of 35 km, a
second epidemic occurred in hospital B between
May 2005 and October 2006, caused by C. difficile
PCR ribotype 027 ⁄ toxinotype III and PCR ribo-
type 017 ⁄ toxinotype VIII. Physicians were
instructed to collect stools from all diarrhoeal
patients whowere hospitalised for >3 days and ⁄ or
who were clinically suspected of CDAD. Samples
were tested within 24 h of arrival at the laboratory
because of possible toxin degradation. The ICTAB
immunoassay was performed at least twice-daily
for as long as the epidemics continued. Following a
negative result, the responsible clinicians were
requested to resample diarrhoeal patients, prefer-
ably within 48 h. When both tests were negative,
CDAD was considered unlikely, and a new test
was requested and the corresponding sample was
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cultured only if clinical suspicion remained. Toxin-
positive faeces were cultured for the presence
of C. difficile and isolates were identified as
described previously [8]. PCR-ribotyping was also
performed as described previously [9].
During the epidemic in hospital A, 50 patients
eventually yielded an ICTAB-positive sample,
with 43 (86%) patients being ICTAB-positive on
initial testing (Table 1). Within 7 days, a second
sample was collected from 131 patients who were
initially ICTAB-negative, of whom three (2%)
were positive with the second sample; thus, 46
(92%) patients were diagnosed correctly with
CDAD following two sequential samples. One
additional patient was ICTAB-positive with a
third sample, also obtained within 7 days, and
three (2%) patients were positive with samples
taken within, on average, 24 days of the first
sample. Considering the interval between sam-
ples, this suggested a new infection. The final four
samples mentioned above were confirmed by
specific culture of C. difficile. Of the ICTAB-
positive samples, 37 were available for culture,
with 33 (90%) yielding C. difficile. Twenty-five
(76%) isolates were identified as C. difficile PCR
ribotype 027. The remaining eight isolates be-
longed to various other PCR ribotypes. A com-
parison of patients with CDAD caused by PCR
ribotype 027 and other PCR ribotypes revealed
no differences in the test results.
In hospital B, 187 patients were diagnosed with
CDAD, of whom 161 (86%) were found to be
ICTAB-positive on initial testing (Table 1). Fol-
lowing a negative first test, 15 patients were
resampled within 1 week, of whom eight were
positive. Thus, CDAD was diagnosed in <1 week
in 169 (90%) of 187 patients. In addition, two
patients were found to be ICTAB-positive with a
second sample obtained 10 days after the first
negative sample. The remaining 16 patients were
diagnosed as positive with samples taken
>14 days after the initial sample. Of the total of
187 ICTAB-positive samples, 165 were cultured
for the presence of C. difficile, with 149 being
culture-positive. Isolates from 147 samples were
available for further typing (Table 1). The epi-
demic strains isolated from patients in hospital B
were identified as PCR ribotypes 017 (toxino-
type VIII; n = 47) and 027 (toxinotype III;
n = 40). The remaining 60 isolates belonged to a
range of PCR ribotypes.
Thus, overall, 12 (5%) of 237 diarrhoeal patients
from hospitals A and B were diagnosed following
the analysis of one or more additional samples
within a week of the initial negative result. An
additional 21 (9%) samples became positive
within, on average, 45 days of the initial sample,
which probably reflects the development of
CDAD in diarrhoeal patients after the observation
period of 1 week. Of 202 positive samples from
hospitals A and B, 20 (10%) were negative by
culture for C. difficile. Importantly, in both hospi-
tals, all retested and subsequently cultured (n = 9)
ICTAB-positive samples that were taken within
1 week of the first negative sample yielded a
positive culture for C. difficile.
In conclusion, testing of multiple stool samples,
collected at an interval of a few days, for C. dif-
ficile toxin appears to be of value for combating
outbreaks of toxin-producing C. difficile. In
particular, when highly epidemic strains are
involved, the additional costs of repeated testing
may be rapidly offset by the benefits associated
with prevention of spread of the disease, includ-
ing preventing closure of wards and expensive
treatment of patients.
Table 1. Value of repeated testing with immunocard toxins A and B (ICTAB) for patients with Clostridium difficile-
associated disease
Patient characteristics
Hospital A Hospital B
All ribotypesa All ribotypes
Subdivided by PCR-ribotypeb
027 017 Other ribotypes
Number of CDAD patients 50 187 40 47 60
ICTAB-positive with first sample (% of all positive patients) 43 (86%) 161 (86%) 36 (90%) 40 (85%) 51 (85%)
ICTAB-positive with repeated sample £1 week
(cumulative % of all positive patients)
4 (94%) 8 (90%) 1 (93%) 3 (91%) 1 (87%)
ICTAB-positive with repeated sample >1 week
(cumulative % of all positive patients)
3 (100%) 18 (100%) 3 (100%) 4 (100%) 8 (100%)
aPCR-ribotyping was only performed for ribotype 027 in hospital A (25 isolates, 76%).
bNot all isolates were available for typing.
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